Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Successful treatment with tandem consolidation using 90yttrium-ibritumomab tiuxetan (Zevalin) and high-dose therapy with autologous PBSCT in a patient with relapsed mantle cell lymphoma presenting as multiple lymphomatous polyposis

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

References

  1. Michopoulos S, Petraki K, Matsouka C, Kastritis E, Chrysanthopoulou H, Dimopoulos MA . Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract. J Clin Oncol 2008; 26: 1555–1557.

    Article  Google Scholar 

  2. Ghielmini M, Zucca E . How I treat mantle cell lymphoma. Blood 2009; 114: 1469–1476.

    Article  CAS  Google Scholar 

  3. Meral M, Demirpence M, Gonen C, Akarsu M, Kayahan H, Demirkan F et al. Diffuse gastrointestinal involvement of mantle cell lymphoma. Turk J Gastroenterol 2008; 19: 117–120.

    PubMed  Google Scholar 

  4. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97: 586–591.

    Article  Google Scholar 

  5. Iwamuro M, Okada H, Kawahara Y, Shinagawa K, Morito T, Yoshino T et al. Endoscopic features and prognoses of mantle cell lymphoma with gastrointestinal involvement. World J Gastroenterol 2010; 16: 4661–4669.

    Article  Google Scholar 

  6. Dreyling M, Hiddemann W . Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program 2009; 1: 542–551.

    Article  Google Scholar 

  7. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463.

    Article  CAS  Google Scholar 

  8. Tobinai K, Watanabe T, Ogura M, Morishima Y, Hotta T, Ishizawa K et al. Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma. Cancer Sci 2009; 100: 158–164.

    Article  CAS  Google Scholar 

  9. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213–5218.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S-G Cho.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, E., Yang, SA., Sohn, HS. et al. Successful treatment with tandem consolidation using 90yttrium-ibritumomab tiuxetan (Zevalin) and high-dose therapy with autologous PBSCT in a patient with relapsed mantle cell lymphoma presenting as multiple lymphomatous polyposis. Bone Marrow Transplant 47, 877–879 (2012). https://doi.org/10.1038/bmt.2011.193

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.193

Search

Quick links